Freenome, Inc. — Form 8-K
Filed November 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Freenome completed IPO on July 21, 2026, raising ~$310M gross proceeds, and received FDA approval for SimpleScreen CRC colorectal cancer test on July 24, 2026. Q3 2026 revenue surged to $183.5M (vs. $1.0M in Q3 2025), driven by $182.5M license/collaboration revenue from Abbott (assumed Exact Sciences agreement); $100M milestone payment triggered by FDA approval. Company holds $430M in cash/securities as of Sept 30, 2026; converted ~$50.5M Abbott convertible note into 3.4M shares at $15/share and ~$6.4M Roche convertible note into 6.4M shares at $12/share upon July business combination close.
Why this rating
IPO capital ($310M) and milestone payment ($100M) represent 4.5x and 1.1x company market cap, respectively. FDA approval and commercial launch de-risk product viability. Revenue 177x YoY growth; positive GAAP net income Q3 vs. prior losses. Material for company scale but execution risk remains on adoption and pipeline advancement.
Tradability signal
SHORT
conviction 19/100 · expected -0.41% over 4 hrs
SHORT (fade the pop): stock already ran +5.2% on this news, and positive calls in this cell have historically given the pop back (-0.43% over 4 hrs, n=441). Reversion play, lower conviction by design. Exit plan: HARD stop 7.7% against entry — 1.4× this stock's measured hourly volatility, fixed, not trailing (trails test terribly on these names) — time exit 4 hrs. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $10.69 ▼ 2.99% | at our read · unknown $11.02 | +10 min · unknown $11.32 ▲ 2.72% | +30 min · unknown $11.22 ▲ 1.86% | +1 hr · unknown $10.99 ▼ 0.27% | +4 hrs · unknown $11.26 ▲ 2.18% |
The stock had already moved +3.09% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.